%PDF-1.4
%
69 0 obj
<>
endobj
66 0 obj
<>
endobj
130 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T20:01:06Z
2024-03-29T07:48:38-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T07:48:38-07:00
application/pdf
Heather
2002-832.nov
uuid:3fecb949-1dd2-11b2-0a00-1c09277d8900
uuid:3fecb94c-1dd2-11b2-0a00-d30000000000
endstream
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
24 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
160 0 obj
[164 0 R]
endobj
161 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(19.)-625.1 (Blumenschein K, Johannesson M. Incorporating quality of life)]TJ
2 -1.25 Td
[(changes into economic evaluations of health care: an overview)64.8 (.)]TJ
0 -1.25 TD
(Health Policy 1996;36:155-66.)Tj
-2 -1.25 Td
[(20.)-625.1 (Jonsson B. Quality of life and health economics: where is the link?)]TJ
2 -1.25 Td
(Scand J Gastroenterol 1996;31 Suppl 221:33-6.)Tj
-2 -1.25 Td
[(21.)-625.1 (von Neumann J, Mor)17.7 (genstern O. )17.7 (Theory of games and behavior)54.8 (.)]TJ
2 -1.25 Td
(Princeton: Princeton University Press; 1953.)Tj
-2 -1.25 Td
[(22.)-625.1 (T)69.9 (orrance GW)91.7 (, )17.7 (Thomas )17.7 (WM, Sackett DL. )54.8 (A)-220.1 (utility maximization)]TJ
2 -1.25 Td
(model for evaluation of health care programs. Health Services Res)Tj
0 Tc 0 Tw T*
[(1972;7:1)36.9 (18-33.)]TJ
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(23.)-625.1 (Bala MV)128.8 (, Mauskopf JA, )17.7 (W)79.9 (ood LL. )17.7 (W)39.8 (illingness to pay as a measure)]TJ
2 -1.25 Td
(of health benefits. Pharmacoeconomics 1999;15:9-18.)Tj
-2 -1.25 Td
[(24.)-625.1 (Gafni )54.8 (A. )17.7 (W)39.8 (illingness to pay in the context of an economic)]TJ
2 -1.25 Td
[(evaluation of healthcare programs: theory and practice. )54.8 (Am J)]TJ
T*
(Managed Care 1997;3 Suppl:S21-32.)Tj
-2 -1.25 Td
[(25.)-625.1 (Hanneman )17.7 (WM. )17.7 (V)110.8 (aluing the environment through contingent)]TJ
2 -1.25 Td
(valuation. J Economic Perspectives 1994;8:19-43.)Tj
-2 -1.25 Td
[(26.)-625.1 (Berwick DM, )17.7 (W)79.9 (einstein MC. )17.7 (What do patients value? )17.7 (W)39.8 (illingness)]TJ
2 -1.25 Td
[(to pay for ultrasound in normal pregnancy)64.8 (. Med Care 1985;)]TJ
0 Tc 0 Tw T*
(23:881-93. )Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(27.)-625.1 (Johannesson M, Johansson PO, J\232nsson B. Economic evaluation of)]TJ
2 -1.25 Td
[(drug therapy)64.8 (. )54.8 (A)-220.1 (review of the contingent valuation method.)]TJ
T*
(Pharmacoeconomics 1992;1:325-37.)Tj
-2 -1.25 Td
[(28.)-625.1 (Hyland ME. Quality of life measures as providers of information on)]TJ
2 -1.25 Td
[(value-for)19.7 (-money of health interventions. Comparison and)]TJ
T*
[(recommendations for practice. Pharmacoeconomics 1997;1)36.8 (1:19-31.)]TJ
-2 -1.25 Td
[(29.)-625.1 (Altman R, )54.8 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
2 -1.25 Td
(classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. )54.8 (Arthritis Rheum 1986;29:1039-49.)]TJ
-2 -1.25 Td
[(30.)-625.1 (Altman R, )54.8 (Alarcon GC, )54.8 (Appelrouth D, et al. )17.7 (The )54.8 (American College)]TJ
2 -1.25 Td
(of Rheumatology criteria for the classification and reporting of)Tj
T*
[(osteoarthritis of the hip. )54.8 (Arthritis Rheum 1991;34:505-14.)]TJ
-2 -1.25 Td
[(31.)-625.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.8 (.)]TJ
2 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
T*
(measuring clinically important patient relevant outcomes to)Tj
T*
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-2 -1.25 Td
[(32.)-625.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.8 (.)]TJ
2 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
T*
(measuring clinically-important patient-relevant outcomes following)Tj
T*
(total hip or knee arthroplasty in osteoarthritis. J Orthop Rheumatol)Tj
0 Tc 0 Tw T*
(1988;1:95-108.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(33.)-625.1 (Bellamy N, Kean )17.7 (WF)79.7 (, Buchanan )17.7 (WW)91.7 (, Gerecz-Simon E, Campbell)]TJ
2 -1.25 Td
(J. Double blind randomized controlled trial of sodium)Tj
T*
[(meclofenamate \(Meclomen\) and diclofenac sodium \(V)128.8 (oltaren\): post)]TJ
T*
[(validation reapplication of the )17.7 (WOMAC Osteoarthritis Index. )]TJ
T*
(J Rheumatol 1992;19:153-9.)Tj
-2 -1.25 Td
[(34.)-625.1 (Direction de la Surveillance de la Sant\216. Indicateurs de sant\216 199\
6.)]TJ
2 -1.25 Td
(Brussels: Minist\217re de la Communaut\216 Fran\215aise. Direction de la\
)Tj
T*
(Surveillance de la Sant\216; 1996:35.)Tj
-2 -1.25 Td
[(35.)-625.1 (Johannesson M, Johansson PO, Kristrom B, et al. )17.7 (W)39.8 (illingness to pay)]TJ
2 -1.25 Td
(for antihypertensive therapy: further results. J Health Econ)Tj
0 Tc 0 Tw T*
(1993;12:95-108. )Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(36.)-625.1 (Johansson PO. Evaluating health risks: an economic approach.)]TJ
2 -1.25 Td
(Cambridge: Cambridge University Press; 1995.)Tj
-2 -1.25 Td
[(37.)-625.1 (Quataert P)110.7 (,)-0.1 ( )17.7 (V)110.8 (an Oyen H, )17.7 (T)69.9 (a)0.3 (f)17.7 (foreau J, et al. Health Interview Survey)64.8 (,)]TJ
2 -1.25 Td
(1997. Protocol for the selection of households and respondents.)Tj
T*
[(S.P)110.7 (.H/EPISERIE No. 12. Brussels: Scientific Institute of Public)]TJ
T*
(Health; 1997.)Tj
31 72.5 Td
[(38.)-625.1 (Gafni )54.8 (A. Using willingness-to-pay as a measure of benefits: what is)]TJ
2 -1.25 Td
(the relevant question to ask in the context of public decision)Tj
T*
(making? Med Dec Making 1991;29:1246-52.)Tj
-2 -1.25 Td
[(39.)-625.1 (Thompson MS, Leighton Read J, Liang M. Feasibility of)]TJ
2 -1.25 Td
(willingness-to-pay measurement in chronic arthritis. Med Dec)Tj
0 Tc T*
(Making 1984;4:195-215.)Tj
-0.00011 Tc -2 -1.25 Td
[(40.)-625.1 (Johannesson M, J\232nsson B, Karlsson G. Outcome measurement in)]TJ
2 -1.25 Td
(economic evaluation. Health Econ 1996;5:279-96.)Tj
-2 -1.25 Td
[(41.)-625.1 (Bleichrodt H, Johannesson M. )54.8 (An experimental test of a theoretical)]TJ
2 -1.25 Td
(foundation for rating-scale valuations. Med Dec Making)Tj
0 Tc 0 Tw T*
(1997;17:208-16.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(42.)-625.1 (Cross MJ, March LM, Lapsley HM, et al. Determinants of)]TJ
2 -1.25 Td
[(willingness to pay for hip and knee joint replacement sur)17.7 (gery for)]TJ
T*
(osteoarthritis. Rheumatol 2000;39:1242-8.)Tj
-2 -1.25 Td
[(43.)-625.1 (Blumenschein K, Johannesson M. Relationship between quality of)]TJ
2 -1.25 Td
(life instruments, health state utilities, and willingness to pay in)Tj
-0.0051 Tc T*
[(patients with asthma. )54.8 (Ann )54.8 (Aller)17.7 (gy )54.8 (Asthma Immunol 1998;80:189-94.)]TJ
-0.00011 Tc -2 -1.25 Td
[(44.)-625.1 (Lundber)17.7 (g L, Johannesson M, Silverdahl M, et al. Quality of life,)]TJ
2 -1.25 Td
(health state utilities and willingness to pay with psoriasis and atopic)Tj
T*
(eczema. Br J Dermatol 1999;141:1067-75.)Tj
-2 -1.25 Td
[(45.)-625.1 (Bosch JL, Hunink MGM. )17.7 (The relationship between descriptive and)]TJ
2 -1.25 Td
(valuational quality-of-life measures in patients with intermittent)Tj
T*
(claudication. Med Dec Making 1996;16:217-25. )Tj
-2 -1.25 Td
[(46.)-625.1 (O\325Brien B, )17.7 (V)59.8 (iramontes JL. )17.7 (W)39.9 (illingness to pay: a valid and reliable)]TJ
2 -1.25 Td
(measure of health state preference? Med Dec Making 1994;)Tj
0 Tc 0 Tw T*
(14:289-97.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(47.)-625.1 (Bala MV)128.8 (, )17.7 (W)79.9 (ood LL, Zarkin GA, et al. )17.7 (V)110.8 (aluing outcomes in health)]TJ
2 -1.25 Td
[(care: )54.8 (A)-220.1 (comparison of willingness to pay and quality-adjusted life)]TJ
T*
(years. J Clin Epidemiol 1998;51:667-76.)Tj
-2 -1.25 Td
[(48.)-625.1 (Cunningham SJ, Hunt NP)110.7 (. Relationship between utility values and)]TJ
2 -1.25 Td
[(willingness to pay in patients under)17.7 (going orthognathic treatment.)]TJ
T*
(Community Dental Health 2000;17:92-6.)Tj
-2 -1.25 Td
[(49.)-625.1 (Thompson MS. )17.7 (W)39.8 (illingness to pay and accept risks to cure chronic)]TJ
2 -1.25 Td
[(disease. )54.8 (Am J Public Health 1986;76:392-6.)]TJ
-2 -1.25 Td
[(50.)-625.1 (Rothfuss J, Mau )17.7 (W)91.8 (, Zeider H, et al. Socioeconomic evaluation of)]TJ
2 -1.25 Td
[(rheumatoid arthritis and osteoarthritis: a literature review)64.8 (. Semin)]TJ
T*
(Arthritis Rheum 1997;25:771-9. )Tj
-2 -1.25 Td
[(51.)-625.1 (Ferraz MB, Maetzel )54.8 (A, Bombardier C. )54.8 (A)-220.1 (summary of economic)]TJ
2 -1.25 Td
(evaluations published in the field of rheumatology and related)Tj
T*
[(disciplines. )54.8 (Arthritis Rheum 1997;40:1587-93.)]TJ
-2 -1.25 Td
[(52.)-625.1 (Slothuus U, Brooks RG. )17.7 (W)39.9 (illingness to pay in arthritis: a Danish)]TJ
2 -1.25 Td
(contribution. Rheumatol 2000;39:791-9.)Tj
-2 -1.25 Td
[(53.)-625.1 (Liljas B, Lindgren B. On individual preferences and aggregation in)]TJ
2 -1.25 Td
(economic evaluation in healthcare. Pharmacoeconomics)Tj
0 Tc 0 Tw T*
(2001;19:323-35.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(54.)-625.1 (Johannesson M, J\232nsson B. Economic evaluation in health care: Is)]TJ
2 -1.25 Td
(there a role for cost-benefit analysis. Health Policy 1991;17:1-23.)Tj
-2 -1.25 Td
[(55.)-625.1 (Burrows C, Brown K. )54.8 (Are any numbers better than no numbers?)]TJ
2 -1.25 Td
(The sorry state of willingness-to-pay and some major)Tj
T*
[(methodological shortcomings. )54.8 (Australian Health Rev 1992;)]TJ
0 Tc 0 Tw T*
(15:135-44.)Tj
-0.00011 Tc 0.02499 Tw -2 -1.25 Td
[(56.)-625.1 (Donaldson C. )17.7 (V)110.8 (aluing the benefits of publicly-provided health care:)]TJ
2 -1.25 Td
(does \322ability to pay\323 preclude the use of \322willingness to pay\323\
? Soc)Tj
T*
(Sci Med 1999;49:551-63.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Ethgen, et al: Health outcome and WOMAC in OA)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2459)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>stream
8;Z\6=a&j[#itt$j>rL3<=;uH-"CTEj>A$m\.O=e-p$s:Du6^h54%;e?Z2QD5@'!_=oP;9l)l_+oX2Z^dFsdY!TOA>t^=sX[`#K8DVi)$nQt*!7
[K?]h`iBK48D^kF`DJ/gT*OQE_Vi][a=<@1AV'TE@6[fraq8U93U''V'A&uB+u1D4
fpL@;j_dUM"fL6GVRHa4?2dF3_4&bLaqQGK-UU,NW'4Cgq1DT>$Pok5iFOI@FGUGe
6]>tflYMSA6eoc6`2@1e_,`a`o_I*HV:(."3,j@Sk/tgW_ds*$*RmKf81+[8qUCckWR2RDQ*aE%
(nd?M<5&A(0e]9^jI'j/mi*T*F$5UBFc;[8uP@4u-uS1c02LB/mi^Do?$@'+^OhJg)V"/Gojb/p1VJD;;Rp
?ckf`%C1/Gjg$\U1f+knRCe"g5@l=;NLG@r)@q@VBo8IHIO4:>Hr'T`d@np,BLS>p
P*?DNYh$+8!(3JFM,^*'Q\bjuV2fpid[t(!J36+kFK:!~>
endstream
endobj
53 0 obj
[/Indexed/DeviceRGB 255 52 0 R]
endobj
52 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
76 0 obj
<>
endobj
72 0 obj
<>
endobj
113 0 obj
<>
endobj
135 0 obj
<>
endobj
73 0 obj
<>
endobj
106 0 obj
<>stream
HU{PS7ᆋBE WHWE 屋!JH GHHEPu-jWu,n7:mg|s;7͜qms躭7-śi=kxlff